June 9, 2020 -- Hong Kong-based WuXi Biologics has signed a 10-year lease for a clinical manufacturing facility in Cranbury, NJ, making it the company's third site in the U.S.
The company will install 6,000-L bioreactors for manufacturing, process development and quality control labs, and associated functional spaces. The 66,000-sq-ft facility is expected to open in late 2020 and will bring 100 new jobs to the region.
WuXi recently purchased land to build a 107,000-sq-ft facility in Worcester, MA, and leased a 33,000-sq-ft site for process development in King of Prussia, PA.
Copyright © 2020 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
